Shortened Antibiotic Treatment of 5 Days in Gram-negative Bacteremia

GNB5 is an investigator-initiated multicentre non-inferiority randomized controlled trial which aims to assess the efficacy and safety of shortened antibiotic for patients hospitalized with a Gram negative bacteremia with a urinary tract source of infection (GNB). Five days after initiation of antimicrobial therapy for GNB, participants are randomized 1:1 to parallel treatment arms: 5 days (intervention) or minimum 7 days (control) of antibiotic treatment. The intervention group discontinues antibiotics at day 5 if clinically stable and afebrile. The control group receives antibiotics for a duration of 7 days or longer at the discretion of the treating physician. The primary outcome is 90-day survival without clinical or microbiological failure to treatment, which will be tested with a non inferiority margin of 10%.

This description comes directly from the study's public registry record.

Sandra Tingsgård, MD  ·  +4520544094  ·  sandra.tingsgaard@regionh.dk

Thomas Benfield, MD DMSc  ·  thomas.lars.benfield@regionh.dk

Always discuss trial participation with your own doctor first.

+ 1 more locations — full list on the registry record.

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.